PMID- 12716526
OWN - NLM
STAT- MEDLINE
DCOM- 20050310
LR  - 20131121
IS  - 1007-3418 (Print)
IS  - 1007-3418 (Linking)
VI  - 11
IP  - 4
DP  - 2003 Apr
TI  - [Quasispecies and mutation of hepatitis B virus polymerase gene in lamivudine- 
      treated patients].
PG  - 235-8
AB  - OBJECTIVE: To study the quasispecies and mutation features of hepatitis B virus 
      polymerase (HBV P) gene in chronic hepatitis B patients before and after 
      lamivudine treatment. METHODS: The HBV P gene was amplificated with PCR and 
      cloned, then single strand conformation polymorphism / heteroduplex analysis 
      (SSCP/HDA) was applied to analyze the quasispecies complexity and mutation 
      characters of HBV P gene. RESULTS: The quasispecies number of HBV P gene before 
      treatment was larger than that after treatment (7 to 14 vs. 4 to 8, t = 3.98, P < 
      0.05). Six patients had one or two predominant quasispecies before therapy, but 
      the percentages of predominant quasispecies were lower than those after therapy 
      (33.3% to 81.8% vs. 78.8% to 90.9%, t = 3.42, P < 0.05). By sequencing the 
      predominant clones, there were 2 patients with M550V/L528M mutation, 3 patients 
      with M550I mutation and 1 patient with wild type after lamivudine therapy. 
      Additionally, there were individualization mutations which had no obvious tender. 
      CONCLUSION: Quasispecies of hepatitis B virus are changed under the selection of 
      lamivudine, meanwhile, the mutation at YMDD motif emerges.
FAU - Huang, Yan-ping
AU  - Huang YP
AD  - Department of Infectious Diseases, Southwest Hospital, Third Military Medical 
      University, Chongqing 400038, China.
FAU - Wang, Yu-ming
AU  - Wang YM
FAU - Lan, Lin
AU  - Lan L
FAU - Fan, Yi
AU  - Fan Y
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhonghua Gan Zang Bing Za Zhi
JT  - Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of 
      hepatology
JID - 9710009
RN  - 0 (Antiviral Agents)
RN  - 0 (DNA, Viral)
RN  - 2T8Q726O95 (Lamivudine)
RN  - EC 2.7.7.7 (DNA-Directed DNA Polymerase)
SB  - IM
MH  - Antiviral Agents/therapeutic use
MH  - DNA, Viral/metabolism
MH  - DNA-Directed DNA Polymerase/genetics
MH  - Female
MH  - Hepatitis B virus/classification/*genetics
MH  - Hepatitis B, Chronic/*drug therapy/virology
MH  - Humans
MH  - Lamivudine/*therapeutic use
MH  - Male
MH  - Point Mutation/*genetics
EDAT- 2003/04/30 05:00
MHDA- 2005/03/11 09:00
CRDT- 2003/04/30 05:00
PHST- 2003/04/30 05:00 [pubmed]
PHST- 2005/03/11 09:00 [medline]
PHST- 2003/04/30 05:00 [entrez]
PST - ppublish
SO  - Zhonghua Gan Zang Bing Za Zhi. 2003 Apr;11(4):235-8.